There are still unanswered questions, for example, do more potent P2Y12 inhibitors combined with a DOAC substitute for triple therapy?
Alternatively login via
Inflammatory bowel disease assessment tools
Hereditary ATTR amyloidosis
Optimising anti-TNF treatment using biosimilars
Chronic Lymphocytic Leukaemia (CLL)
Anticoagulation Therapy for Stroke Prevention
Back to epgonline.org